Skip to main content
Top
Published in: Medical Oncology 2/2010

01-06-2010 | Original Paper

Proliferation inhibition effect of docetaxel combined with cisplatin on osteosarcoma cells

Authors: Wei Jin, Lin Cai, Guangfeng Niu, Hai Tao

Published in: Medical Oncology | Issue 2/2010

Login to get access

Abstract

This research, studies the proliferation inhibition effect of combined use of docetaxel and cisplatin on osteosarcoma cells. The effects of docetaxel and cisplatin used alone and combined on osteosarcoma cell line HOS8603 were examined by means of cell count, morphologic observation, and flow cytometry (FCM). It was found that docetaxel and cisplatin either used alone or in combination, significantly inhibited the proliferation of osteosarcoma cells and apparently induced the apoptosis, and the effect of the combined drugs was better than that of the drugs used alone (growth inhibition ratio ≥59.34%, P < 0.05; apoptosis ratio = 18.31%, P < 0.01). Therefore, the combined use of docetaxel and cisplatin is more effective than either of the drugs used alone in inhibiting the proliferation of osteosarcoma cells.
Literature
1.
go back to reference Gandara DR, Vokes E, Green M, Bonomi P, Devore R, et al. Activity of docetaxel in platinum treated non-small cell lung cancer: results of a phase II multicenter trial. Clin Oncol. 2000;18(1):131–5. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, et al. Activity of docetaxel in platinum treated non-small cell lung cancer: results of a phase II multicenter trial. Clin Oncol. 2000;18(1):131–5.
3.
go back to reference Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22(9):1706–12. doi:10.1200/JCO.2004.08.043.CrossRefPubMed Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004;22(9):1706–12. doi:10.​1200/​JCO.​2004.​08.​043.CrossRefPubMed
4.
go back to reference Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51(18):4845–52.PubMed Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51(18):4845–52.PubMed
5.
go back to reference Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, et al. Sequential events of apoptosis involving docetaxel, a microtubule interfering agent: a cytometric study. BMC Cell Biol. 2006;1(7):6.CrossRef Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, et al. Sequential events of apoptosis involving docetaxel, a microtubule interfering agent: a cytometric study. BMC Cell Biol. 2006;1(7):6.CrossRef
6.
go back to reference Bracarda S. Chemotherapy of prostate cancer: potential role of docetaxel. Tumori. 2001;87(6):A12–4.PubMed Bracarda S. Chemotherapy of prostate cancer: potential role of docetaxel. Tumori. 2001;87(6):A12–4.PubMed
8.
13.
go back to reference Tanaka T, Bai T, Yukawa K, Umesaki N, et al. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Oncol Rep. 2006;15(4):939–47.PubMed Tanaka T, Bai T, Yukawa K, Umesaki N, et al. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Oncol Rep. 2006;15(4):939–47.PubMed
14.
go back to reference Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW, et al. Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel. Ai Zheng. 2006;25(4):398–403.PubMed Yan XJ, Liang LZ, Zeng ZY, Shi Z, Fu LW, et al. Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel. Ai Zheng. 2006;25(4):398–403.PubMed
Metadata
Title
Proliferation inhibition effect of docetaxel combined with cisplatin on osteosarcoma cells
Authors
Wei Jin
Lin Cai
Guangfeng Niu
Hai Tao
Publication date
01-06-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9240-x

Other articles of this Issue 2/2010

Medical Oncology 2/2010 Go to the issue

Letter to the editor

Letter to the editor

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.